

Supplementary Table 1. Any adverse event (AE) and GI AEs at univariate and multivariate regression.

Variable	Any AE			
	Univariate		Multivariate	
	OR (95% CI)	p	OR (95% CI)	p
Age	0.96 (0.95-0.97)	<0.0005	0.96 (0.95-0.98)	<0.0005
Male gender	0.47 (0.32-0.68)	<0.0005	0.51 (0.35-0.75)	0.001
Disease duration	0.97 (0.96-0.99)	0.006	0.99 (0.97-1.01)	0.504
Any therapy	1.38 (0.92-2.07)	0.118		
Mesalamine	1.14 (0.80-1.63)	0.473		
Steroids	0.98 (0.32-2.95)	0.967		
Azathioprine	0.42 (0.19-0.94)	0.034	0.39 (0.16-0.90)	0.028
Anti-TNF α	2.01 (1.22-3.33)	0.006	1.53 (0.89-2.64)	0.128
Vedolizumab	0.99 (0.46-2.12)	0.974		
Ustekinumab	1.04 (0.43-2.49)	0.933		
Previous COVID	1.96 (1.02-3.76)	0.042	2.31 (1.14-4.69)	0.021
Vaccine type	1.83 (0.70-4.81)	0.219		
Remission of disease	0.92 (0.58-1.46)	0.730		
State of mind before vaccine	0.99 (0.86-1.14)	0.879		
State of mind after vaccine	0.96 (0.87-1.06)	0.386		

Variable	Gastrointestinal AEs			
	Univariate		Multivariate	
	OR (95% CI)	p	OR (95% CI)	p
Age	0.96 (0.95-0.98)	<0.0005	0.97 (0.95-0.98)	<0.0005
Male gender	0.65 (0.39-1.06)	0.086		
Disease duration	0.99 (0.96-1.00)	0.289		
Any therapy	0.97 (0.56-1.67)	0.901		
Mesalamine	0.86 (0.53-1.41)	0.556		
Steroids	0.99 (0.21-4.54)	0.985		
Azathioprine	1.00 (0.37-2.70)	0.993		
Anti-TNF α	1.04 (0.53-2.03)	0.912		
Vedolizumab	1.52 (0.59-3.88)	0.382		
Ustekinumab	1.29 (0.42-3.95)	0.654		
Previous COVID	1.80 (0.84-3.83)	0.128		
Vaccine type	0.67 (0.15-2.97)	0.597		
Remission of disease	0.42 (0.24-0.73)	0.002	0.43 (0.24-0.77)	0.004
State of mind before vaccine	1.02 (0.84-1.24)	0.822		
State of mind after vaccine	0.96 (0.84-1.10)	0.561		